Private markets investment management firm Hamilton Lane has announced that its board of directors elected Michael Schmertzler as a new independent director, effective July 22. Schmertzler’s appointment constitutes the fifth independent director to be named to the board, serving alongside the firm’s three executive directors.
Schmertzler brings extensive investment, corporate finance and governance experience to the HLNE Board. Since 1998, he has served as a lecturer and adjunct professor at Yale University in the Department of Economics and School of Management and during that time was also a visiting professor at Yale-NUS College Singapore.
He serves as chairman and director of PTC Therapeutics, a publicly traded biotechnology company focused on treatments for rare genetic disorders. He is also chairman and a director of Berryville Holdings, which develops attribution and protection systems for the defense and intelligence community, and of Dispel, a provider of
